{"filing":{"accession_number":"0001867096-26-000034","cik":"0001867096","ticker":"XERS","company_name":"Xeris Biopharma Holdings, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"xers-20260604.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/xers-20260604.htm"},"events":[{"id":6683,"run_id":5850,"accession_number":"0001867096-26-000034","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from Xeris Biopharma's 2026 Annual Meeting held on June 4, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Dawn Halkuff and John Johnson), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote counts and quorum information are characteristic of mandatory shareholder meeting result disclosures.","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4796,"accession_number":"0001867096-26-000034","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Xeris Biopharma's 2026 Annual Meeting held on June 4, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Dawn Halkuff and John Johnson), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote counts and quorum information are characteristic of mandatory shareholder meeting result disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:15:06.282339+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4796,"accession_number":"0001867096-26-000034","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Xeris Biopharma's 2026 Annual Meeting held on June 4, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Dawn Halkuff and John Johnson), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote counts and quorum information are characteristic of mandatory shareholder meeting result disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:15:06.282339+00:00","company_name":"Xeris Biopharma Holdings, Inc.","ticker":"XERS","filing_date":"2026-06-05"}]}